Who are NK105's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Colchicine Pill, Carboplatin+Paclitaxel, Cisplatin and Docetaxel, Docetaxel, Cisplatin, similar placebo to mebendazole, Abraxane (Maintenance).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nk105.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

NK105 — Competitive Intelligence Brief

NK105 (NK105) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule inhibitor. Area: Oncology.

phase 3 Microtubule inhibitor Beta-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

NK105 (NK105) — Nippon Kayaku Co., Ltd.. NK105 is a nanosomal formulation of paclitaxel, a microtubule inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NK105 TARGET	NK105	Nippon Kayaku Co., Ltd.	phase 3	Microtubule inhibitor	Beta-tubulin
Colchicine Pill	Colchicine Pill	Brigham and Women's Hospital	marketed	Microtubule inhibitor / Anti-inflammatory agent	Beta-tubulin
Carboplatin+Paclitaxel	Carboplatin+Paclitaxel	AstraZeneca	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)
Cisplatin and Docetaxel	Cisplatin and Docetaxel	Swiss Cancer Institute	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (cisplatin); beta-tubulin (docetaxel)
Docetaxel, Cisplatin	Docetaxel, Cisplatin	Samsung Medical Center	phase 3	Chemotherapy combination (taxane + platinum agent)	Beta-tubulin (docetaxel); DNA (cisplatin)
similar placebo to mebendazole	similar placebo to mebendazole	Swiss Tropical & Public Health Institute	phase 3	Anthelmintic	Beta-tubulin
Abraxane (Maintenance)	Abraxane (Maintenance)	Celgene	phase 3	Microtubule stabilizer (taxane)	Beta-tubulin / microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microtubule inhibitor class)

Ma Fei，MD · 2 drugs in this class
Eisai Co., Ltd. · 1 drug in this class
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nippon Kayaku Co., Ltd. · 1 drug in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NK105 — Competitive Intelligence Brief. https://druglandscape.com/ci/nk105. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab